Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I

Musetti, Veronica; Masotti, Silvia; Prontera, Concetta; Storti, Simona; Ndreu, Rudina; Zucchelli, G.C.; Passino, Claudio; Emdin, Michele; Clerico, Aldo

doi:10.1515/cclm-2018-0054

Cited by 33 publications

(23 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the cut-off value recommended by all the international guidelines for the diagnosis of MI) [54,55]. However, only after the year 2015 some high-sensitivity methods for cardiac troponins (hs-cTn) allowed a reliable determination of cTn distribution parameters in the most part of healthy subjects [56][57][58][59][60][61], in accordance with quality specifications required by the most recent international guidelines [54,55].…”

Section: Cardiac Troponin I and Tmentioning

confidence: 99%

See 1 more Smart Citation

Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers

Clerico

Zaninotto

Passino

et al. 2020

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

In recent years, the formulation of some immunoassays with high-sensitivity analytical performance allowed the accurate measurement of cardiac troponin I (cTnI) and T (cTnT) levels in reference subjects. Several studies have demonstrated the association between the risk of major cardiovascular events and cardiac troponin concentrations even for biomarker values within the reference intervals. High-sensitivity cTnI and cTnT methods (hs-cTn) enable to monitor myocardial renewal and remodelling, and to promptly identify patients at highest risk ofheart failure. An early and effective treatment of individuals at higher cardiovascular risk may revert the initial myocardial remodelling and slow down heart failure progression. Specific clinical trials should be carried out to demonstrate the efficacy and efficiency of the general population screening by means of cost-benefit analysis, in order to better identify individuals at higher risk for Heart Failure (HF) progression with hs-cTn methods.

show abstract

Section: Cardiac Troponin I and Tmentioning

confidence: 99%

“…Using these hs-cTn methods [56][57][58][59][60][61], more accurate risk stratification was finally achieved in large cohorts from the general population [48][49][50][62][63][64][65][66][67][68][69][70]. In particular, in 2017 Willeit et al [66] [66].…”

Section: Cardiac Troponin I and Tmentioning

confidence: 99%

Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers

Clerico

Zaninotto

Passino

et al. 2020

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

show abstract

“…Finally, the index of individuality is calculated according to Eq. (1) [5,6], where CV a is an estimation of analytical imprecision (expressed as CV) of a specific hs-cTn method [14,19,25,[40][41][42][43]:…”

Section: Parameters Of Biological Variationmentioning

confidence: 99%

Clinical relevance of biological variation of cardiac troponins

Clerico

Padoan

Zaninotto

et al. 2020

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

The high-sensitivity immunoassays for cardiac troponin I (hs-cTnI) and cardiac troponin T (hs-cTnT) are recommended by all the most recent international guidelines as gold standard laboratory methods for the detection of myocardial injury and diagnosis of acute myocardial infarction (AMI). In this review article, the Authors aimed at discussing the relevant biochemical, physiological, and clinical issues related to biological variability of cTnI and cTnT. Cardiac troponins, measured with hs-cTn methods, show a better clinical profile than the other cardio-specific biomarkers (such as the natriuretic peptides, BNP and NT-proBNP). In particular, the hs-cTn methods are characterized by a low intra-individual index of variation (<0.6) and reduced analytical imprecision (about 5% CV) at the clinical cut-off value (i.e., the 99th percentile URL value). Moreover, recent studies have reported that differences between two hs-cTn measured values (RCV) >30% can be considered statistically significant. These favourable biological characteristics and analytical performance of hs-cTn methods significantly improved the accuracy in the diagnostic process of acute coronary syndromes (ACS) in patients admitted to emergence department. In addition, several studies have demonstrated the clinical usefulness of cardiovascular risk evaluation with hs-cTn methods in some groups of patients with clinical conditions at high cardiovascular risk (such as systemic hypertension, severe obesity, diabetes mellitus, renal insufficiency, and chronic obstructive pulmonary disease). However, screening programs in the general population with hs-cTn methods for cardiovascular risk stratification require further investigation to define the optimal target populations, timing of measurement, and preventive interventions.

show abstract

“…We measured Troponin-I with a validated assay routinely used by our institution at the time of our study. We do recognise however that this assay has been superceded by more highly sensitive measures of troponin-I with lower limits of detection and which have shown increased troponin-I levels above the 99th percentile upper reference limit in the majority of HF patients [60][61][62]. Utilising these newer assays may have enabled better troponin-I characterisation and profiling between our groups.…”

Section: Plos Onementioning

confidence: 97%

Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach

et al. 2020

View full text Add to dashboard Cite

on behalf of the NIHR Leicester Cardiovascular Biomedical Research Centre in keeping with the guidance for governance of the study. damage (BNP, pro-BNP, N-terminal pro-atrial natriuretic peptide and troponin-I) were higher in HFrEF compared to HFpEF; p<0.0001. Focal fibrosis was associated with galectin3, GDF-15, MMP-3, MMP-7, MMP-8, BNP, pro-BNP and NTproANP; p<0.05. Diffuse fibrosis was associated with GDF-15, Tenascin-C, MMP-2, MMP-3, MMP-7, BNP, proBNP and NTproANP; p<0.05. Composite event rates (median 1446 days follow-up) did not differ between HFpEF and HFrEF (Log-Rank p = 0.784). Conclusions HFpEF is a distinct pathophysiological entity compared to age-and sex-matched HFrEF and controls. HFpEF and HFrEF are associated with similar adverse outcomes. Inflammation is common in both HF phenotypes but cardiomyocyte stretch/stress is greater in HFrEF.

show abstract

Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin I

Cited by 33 publications

References 8 publications

Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers

Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers

Clinical relevance of biological variation of cardiac troponins

Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach

Contact Info

Product

Resources

About